Compare DexCom, Inc. (DXCM) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while JPMorgan Ultra Short Income ETF trades at $50.49. The key difference: DexCom, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | JPST | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $50.78 |
52-Week Low | $54.84 | $50.40 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.485, up 0.03% on the day. The technical outlook is bearish based on moving averages, though oscillators are neutral. The ETF focuses on high-quality, short-term bonds, offering low duration risk and current income. Recent news highlights strong inflows into active ETFs, with JP Morgan leading in June 2026 flows (ETF Trends, 2026-07-07).
JPST provides a cash-alternative for risk-averse investors, with a stable dividend history. Key risks include interest rate sensitivity and credit spread changes. The fund's conservative profile suits those seeking capital preservation amid market volatility, but limited upside potential exists compared to equity ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
